探路者
临床试验
医学
危险系数
危害
临床研究设计
肺癌
癌症
医学物理学
计算机科学
肿瘤科
内科学
置信区间
图书馆学
有机化学
化学
作者
Ruishan Liu,Shemra Rizzo,Samuel Whipple,Navdeep Pal,Arturo López Pineda,Michael W. Lu,Brandon Arnieri,Ying Lü,William B. Capra,Ryan Copping,James Zou
出处
期刊:Nature
[Nature Portfolio]
日期:2021-04-07
卷期号:592 (7855): 629-633
被引量:299
标识
DOI:10.1038/s41586-021-03430-5
摘要
There is a growing focus on making clinical trials more inclusive but the design of trial eligibility criteria remains challenging1–3. Here we systematically evaluate the effect of different eligibility criteria on cancer trial populations and outcomes with real-world data using the computational framework of Trial Pathfinder. We apply Trial Pathfinder to emulate completed trials of advanced non-small-cell lung cancer using data from a nationwide database of electronic health records comprising 61,094 patients with advanced non-small-cell lung cancer. Our analyses reveal that many common criteria, including exclusions based on several laboratory values, had a minimal effect on the trial hazard ratios. When we used a data-driven approach to broaden restrictive criteria, the pool of eligible patients more than doubled on average and the hazard ratio of the overall survival decreased by an average of 0.05. This suggests that many patients who were not eligible under the original trial criteria could potentially benefit from the treatments. We further support our findings through analyses of other types of cancer and patient-safety data from diverse clinical trials. Our data-driven methodology for evaluating eligibility criteria can facilitate the design of more-inclusive trials while maintaining safeguards for patient safety. Trial Pathfinder uses data from electronic health records of patients with cancer to evaluate eligibility criteria and broaden restrictive criteria, which facilitates the design of more-inclusive trials while maintaining safeguards for patient safety.
科研通智能强力驱动
Strongly Powered by AbleSci AI